Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy By Ogkologos - August 25, 2025 616 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative Group Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Cancer Won’t Wait: “I prayed she would see her daughter start... October 11, 2021 Preparing for your COVID-19 Vaccine: What to Ask your Provider February 1, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib December 16, 2020 Nursing Professor Who Used Her Breast Cancer Diagnosis as a Teaching... December 7, 2020 Load more HOT NEWS Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... EMA Recommends Granting a Marketing Authorisation for Lisocabtagene Maraleucel Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma For Some Women with Breast Cancer, Cost Influences Decisions about Surgery
